Acurx Pharmaceuticals, Inc. Announces Exercise of Warrants for $2.67 Million Gross Proceeds

Acurx Announces Publication in Lancet Microbe of Phase 2b Clinical Trial Data for Ibezapolstat in CDI

2025 Annual Meeting of Stockholders

Jul 17, 2025 • 10:00am EDT

Alliance Global Partners (A.G.P) Healthcare Company Showcase

May 21, 2025 • 9:00am EDT